secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spyre Therapeutics, Inc. (SYRE)
CIK:        0001636282
Form:       8-K
Filed at:   2023-08-11T23:59:59+00:00
Accession:  0000950170-23-041586
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aeglea closes Spyre asset acquisition, raises $210M, sells pegzilarginase, reports Q2 loss
--------------------------------------------------------------------------------

- Acquired Spyre's IBD pipeline (α4β7 and TL1A) for stock; raised $210M gross via Series A preferred private placement.
- Sold pegzilarginase rights to Immedica for $15M upfront + up to $100M milestones; net proceeds to CVR holders.
- Cash and equivalents $236.7M at June 30, including $210M financing; Q2 net loss $217.1M from acquisition-related charges.
- Net loss includes $130.5M acquired IPR&D expense and $58.2M forward contract liability expense.
- Expect SPY001 FIH study in H1 2024; SPY002 FIH study in H2 2024; healthy volunteer data by end-2024 / H1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636282/000095017023041586/0000950170-23-041586-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636282/000095017023041586/agle-20230811.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-041586

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer